Benefits of tiotropium/olodaterol compared with tiotropium in patients with COPD receiving only LAMA at baseline: pooled analysis of 4 clinical trials Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more Year: 2019
A multi-centre doubleblind randomised study examining the clinical outcome of treatment of the first asthma exacerbation with salmeterol xinafoate/fluticasone propionate combination product versus prednisolone Source: Eur Respir J 2003; 22: Suppl. 45, 287s Year: 2003
Comparison of cardiovascular safety in a pooled analysis of COPD trials comparing tiotropium with salmeterol Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD Source: Eur Respir J 2014; 44: 1548-1556 Year: 2014
Cardiac events among patients with CV comorbidities: Pooled analysis of COPD trials comparing tiotropium with salmeterol Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
Efficacy and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: a double-blind, randomised controlled trial Source: ERJ Open Res, 7 (3) 00255-2021; 10.1183/23120541.00255-2021 Year: 2021
A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo Source: Eur Respir J 2006; 28: Suppl. 50, 764s Year: 2006
A pilot study comparing tiotropium to salmeterol plus fluticasone in moderate COPD Source: Eur Respir J 2005; 26: Suppl. 49, 124s Year: 2005
Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the UPLIFT trial Source: Annual Congress 2009 - Functional insights into COPD Year: 2009
Health care resource utilization following addition of montelukast or salmeterol to fluticasone in patients with inadequately controlled asthma (IMPACT trial) Source: Eur Respir J 2004; 24: Suppl. 48, 127s Year: 2004
Indacaterol once-daily improves dyspnoea in COPD patients: a 26-week placebo-controlled study with open-label tiotropium comparison Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009
A randomised, open-label study of umeclidinium versus glycopyrronium in patients with COPD Source: ERJ Open Res 2016: 00101-2015 Year: 2016
Late Breaking Abstract - A randomized clinical study to assess the impact of budesonide/formoterol (BUD/FM) pMDI medication reminders on adherence in COPD patients Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet? Year: 2018
Safety and tolerability of indacaterol once-daily in COPD patients versus placebo and tiotropium: a 26-week study Source: Annual Congress 2009 - New bronchodilators Year: 2009
A novel study design for the comparison between once-daily QVA149 and twice-daily salmeterol/fluticasone on the reduction of COPD exacerbations: The FLAME study Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013
Once-daily QVA149 improves dyspnoea and health status compared with tiotropium plus formoterol in patients without ICS use: A post-hoc analysis of the QUANTIFY study Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015
How to reduce COPD exacerbations with inhaled drugs? A pooled analysis of randomized trials Source: Annual Congress 2008 - Organisation of care and management of COPD Year: 2008
Twice-daily aclidinium bromide in COPD patients: A pooled analysis of lung function in the ACCORD-COPD I and ATTAIN trials Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012
Switch from LABA+ICS to a LABA/LAMA combination in symptomatic women with COPD – an analysis of the observational DACCORD study Source: International Congress 2018 – Pharmacological management of COPD Year: 2018
Indacaterol/glycopyrronium vs tiotropium or glycopyrronium in treatment naive COPD patients: a pooled analysis Source: International Congress 2018 – COPD management Year: 2018